4-Methylumbelliferyl butyrate (MUB) is a synthetic fluorescent substrate used in the study of various biological processes. Its structure consists of a butyrate group linked to the 4-methylumbelliferone molecule, which is a fluorescent compound. MUB is primarily used as a substrate for the enzyme butyrylcholinesterase (BuChE), and its hydrolysis can be easily monitored by measuring the fluorescence of the released 4-methylumbelliferone. This property makes it a valuable tool for studying BuChE activity in various biological systems, including cell cultures, tissues, and biological fluids. The synthesis of MUB involves a condensation reaction between butyryl chloride and 4-methylumbelliferone. In research, MUB is studied for its ability to: (1) Measure BuChE activity: MUB hydrolysis by BuChE produces 4-methylumbelliferone, which emits fluorescence detectable at a specific wavelength. This allows for the quantification of BuChE activity in various samples. (2) Screen for potential inhibitors of BuChE: By measuring the inhibition of MUB hydrolysis by BuChE in the presence of potential inhibitors, researchers can identify compounds that may be effective for treating diseases related to BuChE dysfunction. (3) Investigate the role of BuChE in different biological processes: MUB is a useful tool for investigating the role of BuChE in various physiological and pathological processes, such as neurotransmission, inflammation, and drug metabolism. (4) Monitor BuChE activity in vivo: MUB can be used to monitor BuChE activity in living organisms, providing insights into the enzyme's role in health and disease. In summary, 4-methylumbelliferyl butyrate (MUB) is a valuable research tool that plays a crucial role in studying butyrylcholinesterase (BuChE) activity, its inhibition, and its involvement in various biological processes.'
4-methylumbelliferyl butyrate: substrate from butyrate esterase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
4-methylumbelliferyl butyate : A member of the class of coumarins that is 4-methylumbelliferone in which the hydroxyl hydrogen is replaced by a butyryl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 87247 |
| CHEMBL ID | 1601816 |
| CHEBI ID | 91120 |
| SCHEMBL ID | 145934 |
| MeSH ID | M0158102 |
| Synonym |
|---|
| (4-methyl-2-oxo-chromen-7-yl) butanoate |
| 4-methyl-2-oxo-2h-chromen-7-yl butyrate |
| AE-848/30701048 |
| TIMTEC1_005087 |
| OPREA1_700096 |
| MLS000699332 |
| smr000225095 |
| 4-methylumbelliferone butyrate |
| 17695-46-4 |
| 4-methylcoumarin-7-yl butyrate |
| butanoic acid, 4-methyl-2-oxo-2h-1-benzopyran-7-yl ester |
| nsc152103 |
| butyryl 4-methylumbelliferone |
| nsc-152103 |
| butyric acid, ester with 7-hydroxy-4-methylcoumarin |
| nsc-688808 |
| nsc688808 |
| M-5520 |
| 4-methylumbelliferyl butyrate |
| 4-methylumbelliferyl butyrate, suitable for fluorescence, >=95% (hpce) |
| HMS1548H05 |
| (4-methyl-2-oxochromen-7-yl) butanoate |
| AKOS003028075 |
| NCGC00247167-01 |
| HMS2558H03 |
| nsc 152103 |
| unii-thy0nz2z72 |
| 4-methyl-2-oxo-2h-1-benzopyran-7-yl butyrate |
| einecs 241-694-7 |
| 4-methylumbelliferone butanoate |
| thy0nz2z72 , |
| SCHEMBL145934 |
| CHEBI:91120 |
| 7-(propylcarbonyl)oxy-4-methyl-2h-1-benzopyran-2-one |
| 4-methylumbelliferyl butyate |
| 4-methyl-2-oxo-2h-1-benzopyran-7-yl butanoate |
| 4-methylumbelliferyl butanoate |
| DTXSID0066246 |
| CHEMBL1601816 |
| J-100195 |
| mfcd00038087 |
| AS-70118 |
| 4-methyl-2-oxo-2h-chromen-7-yl butanoate |
| Q27163062 |
| FT-0733433 |
| butyric acid 4-methyl-2-oxo-2h-chromen-7-yl ester |
| coumarin, 7-hydroxy-4-methyl-, butyrate |
| citricacidzincsaltdihydrate |
| D97347 |
| A881494 |
| CS-0109112 |
| EN300-1708805 |
| Role | Description |
|---|---|
| chromogenic compound | Colourless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into coloured compounds. They are used in biochemical assays and in diagnosis as indicators, particularly in the form of enzyme substrates. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| coumarins | |
| butyrate ester | Any carboxylic ester where the carboxylic acid component is butyric acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 35.4813 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 37.9330 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 37.6188 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
| ClpP | Bacillus subtilis | Potency | 25.1189 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
| TDP1 protein | Homo sapiens (human) | Potency | 16.3601 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 31.6228 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 28.1838 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 35.4813 | 4.4668 | 18.3916 | 35.4813 | AID1467; AID2107 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 35.4813 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2112; AID2242 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 21.3349 | 1.1998 | 14.6419 | 50.1187 | AID720540 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 25.1189 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
| geminin | Homo sapiens (human) | Potency | 32.6427 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 35.4813 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 35.4813 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
| C-terminal-binding protein 1 | Homo sapiens (human) | Potency | 16.9469 | 0.3014 | 9.3210 | 19.0148 | AID720541 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | C-terminal-binding protein 1 | Homo sapiens (human) |
| nucleoplasm | C-terminal-binding protein 1 | Homo sapiens (human) |
| presynaptic active zone cytoplasmic component | C-terminal-binding protein 1 | Homo sapiens (human) |
| glutamatergic synapse | C-terminal-binding protein 1 | Homo sapiens (human) |
| GABA-ergic synapse | C-terminal-binding protein 1 | Homo sapiens (human) |
| transcription repressor complex | C-terminal-binding protein 1 | Homo sapiens (human) |
| nucleus | C-terminal-binding protein 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.70) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||